Narcolepsy
RecruitingEfficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1
- Disease:Narcolepsy
- Substances:Alks 2680
Spain- Participants:18–64 years · 65+ years
- Substances:Alks 2680
- Sponsor:Alkermes Inc.
Rare diseases
Investigational molecules
Locations
Back to Spain71 clinical trials in Vitoria, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in SpainEnsayosClinicos.es(opens in a new tab)
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Spain
Spain
SpainThe busiest research cities in the country
What the registry says about research in the country
Innovative trials focusing on breast cancer treatments, including studies of atezolizumab with chemotherapy and novel approaches for HER2-positive breast cancer. Additional research explores treatments for bladder cancer and pancreatic adenocarcinoma.
Researchers are evaluating both immunotherapy and targeted treatments to improve patient outcomes.
Comprehensive studies examining treatments for Sjögren's Syndrome and systemic lupus erythematosus. Research includes evaluation of novel therapies like dazodalibep and efgartigimod for managing autoimmune conditions.
Focus on long-term safety and efficacy of new therapeutic approaches.
Studies investigating treatments for multiple sclerosis, narcolepsy, and idiopathic hypersomnia. Research includes evaluation of remibrutinib and novel sleep disorder therapies.
Emphasis on developing targeted treatments for better disease control.
Tell us about your condition – we search every trial in Europe and connect you with the right site.